Biogen quarter-one results disappoint Wall Street as Tecfidera sales slow

April 24, 2015 11:38 AM

51 0

Biogen quarter-one results disappoint Wall Street as Tecfidera sales slow

(Reuters) - Biogen Inc posted lower-then-expected quarterly profit and revenue as its key oral multiple sclerosis (MS) drug Tecfidera showed signs of slowing growth, sending the company's shares down 3 percent in premarket trading on Friday.

The drug's sales have shown little sign of slowing after falling short of analysts' estimates for the first time in the third quarter of 2014. Sales of Tecfidera beat the average analyst estimate by about $36 million last quarter.

Read more

To category page

Loading...